$1,000 follows their calls into $901
bluefinsashimi@bluefinsashimiI own both $SPCX and $ASTS . @SpaceX needs the competition, without it, the monopoly risk is real. There’s plenty of room for both!
bluefinsashimi@bluefinsashimi$IBRX - Sepsis will be a thing of the past! [w/ $INKT]
Katrina Helle@KatrinaHelle$IBRX Forget the cancer treatment headline for a minute. The Phase 2 sepsis trial was expected to be fully enrolled this month. The trial tracks 28-day mortality so its gonna be quick. Results in about a year. Nothing really works for sepsis. This means there is a good chance
bluefinsashimi@bluefinsashimi$IBRX - Short sellers have blatantly disrespected Saudi and UAE sovereign capital, they're mocking #Anktiva’s approval. @PIF_en @Mubadala Time for these funds to go 'all in' and squeeze the life out of them as revenge. In the Gulf, respect is never optional. @ImmunityBio
0:06bluefinsashimi@bluefinsashimi$IBRX Just in: UAE regulators just gave #ANKTIVA (@ImmunityBio’s cancer immunotherapy) the broadest approval it’s ever received anywhere in the world. For the first time, a country has cleared it for the full range of hard-to-treat bladder cancer that stops responding to
bluefinsashimi@bluefinsashimi$ASTS panic fire sales are the best opportunities
